Description
Fibronostics, a global leader in non-invasive, AI-driven diagnostics for NASH patients, announced today it has secured $6.5 million in funding. In addition to the financing, Sven Henrichwark, PhD, has been named the company's CEO.
FundzWatch™ Score
77
Medium Activity
Buyer Intent Analysis
Get personalized insights on buying likelihood